#ASCO26: New data released for VEGF bispecifics from BioNTech-BMS, Pfizer-3SBio

Much of the attention heading into the annual ASCO meeting next week has focused on Summit Therapeutics and Akeso’s plenary presentation for their bispecific drug ivonescimab. But two of ivonescimab’s biggest competitors are also releasing ...